Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Aug 06, 2013
PTC THERAPEUTICS TO PRESENT AT WEDBUSH CONFERENCE SOUTH PLAINFIELD, NJ – August 6, 2013 –PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Shane Kovacs, Chief Financial Officer of PTC Therapeutics will present a company overview at the Wedbush Securities Life Sciences Management
Additional Formats
Aug 05, 2013
PTC THERAPEUTICS TO HOST SECOND QUARTER 2013 FINANICAL RESULTS CONFERENCE CALL AND WEBCAST SOUTH PLAINFIELD, NJ – August 5, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will report financial results for the second quarter ended June 30, 2013 following the
Additional Formats
Jun 25, 2013
PTC Therapeutics Closes Initial Public Offering SOUTH PLAINFIELD, NJ – June 25, 2013 – PTC Therapeutics, Inc. (PTC) (NASDAQ: PTCT) today announced the closing of its initial public offering of 9,627,800 shares of common stock at a public offering price of $15.00 per share, before
Additional Formats
Jun 20, 2013
PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING SOUTH PLAINFIELD, NJ – June 20, 2013 – PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts.
Additional Formats
Jun 03, 2013
PTC THERAPEUTICS APPOINTS SHANE KOVACS AS CHIEF FINANCIAL OFFICER SOUTH PLAINFIELD, NJ – June 3, 2013 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Shane Kovacs as Chief Financial Officer, reporting to Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. Mr.
Additional Formats
May 16, 2013
PTC THERAPEUTICS, INC. FILES REGISTRATION STATEMENT FOR PROPOSED INITIAL PUBLIC OFFERING South Plainfield, NJ—May 16, 2013—PTC Therapeutics, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to
Additional Formats
Apr 23, 2013
PTC THERAPEUTICS APPOINTS MARK ROTHERA AS CHIEF COMMERCIAL OFFICER SOUTH PLAINFIELD, NJ – April 23, 2013 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Mark A. Rothera as Chief Commercial Officer, reporting to Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. Mr.
Additional Formats
Mar 07, 2013
-Funds to support Phase 3 confirmatory trials of ataluren-
Additional Formats
Dec 06, 2012
Enrollment for a Global Confirmatory Phase 3 Clinical Trial Planned for 1Q13
Additional Formats
Supporting Materials
Nov 06, 2012
SOUTH PLAINFIELD, NJ – November 6, 2012 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Geoffrey McDonough, M.D., to the company's Board of Directors. Dr. McDonough is the President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi), a leading European specialty
Additional Formats